Sabinsa is marking a major milestone: The company was founded by Dr. Muhammed Majeed 35 years ago, entering the U.S. in 1988 as an importer of generic drugs. Throughout the decades, the Sami-Sabinsa Group has become a world-renowned player in the nutraceutical and cosmeceutical ingredients business with product lines diversified into standardized herbal extracts, fine & specialty chemicals, probiotics, and enzymes.
In addition to the U.S., Sami-Sabinsa has expanded into several geographies, including the UK, France, Hungary, and Spain, plus offices in Germany and Poland. The company employs more than 1,400 workers globally, across 17 countries, and multiple key associates have more than 25 years of in-house expertise. That includes Ms. Asha Ramesh, CEO of Sabinsa USA, who has been with the company since 1994 and recently spoke with WholeFoods Magazine to share what sets the company apart.
"As we celebrate this momentous occasion, we remain committed to delivering innovative and sustainable products and poised to continuously expand our market share," said Dr. Majeed, Founder & Group Chairman, Sami-Sabinsa Group. "I would like to thank our customers, business supply-chain and other service partners, and the dedicated staff who have made this journey possible. While celebrating the past, we look forward to new accomplishments and milestones in the coming years."
Recently, Sami-Sabinsa unveiled it's 9th manufacturing facility. Sami Nutraceuticals Pvt. Ltd. is a new state-of-the-art unit-1 greenfield manufacturing facility in Hassan, India. It will serve the nutraceutical and pharmaceutical majors in various regulated markets globally, according to a press release. With the addition of Sami Nutraceuticals, Sami-Sabinsa has boosted its annual throughput to more than 2,000 tons and the combined plant area to 1.75 million square feet, according to the company.
Sami-Sabinsa also is in the final phases of completion of its unit-2 manufacturing facility at Hassan, India, which is expected to be completed by December 2023.
Sami-Sabinsa has been recognized by international entities for its innovations, most recently being awarded the 2023 ABC Varro E. Tyler Commercial Investment in Phytomedicinal Research Award from the American Botanical Council (ABC). Sabinsa also received the Best Technology Innovation award for its LactoSpore product at the Food Formula Innovation Show in China.
Sami-Sabinsa uses Intellectual Property (IP) to support its ingredients. The current suite of patents exceeds 440, including the U.S. and other countries. This, according to the releases, enables Sami-Sabinsa's novel ingredients to take the lead in international markets. The research-focused company publishes studies in support of product safety and efficacy, and works to set the standard for best practices throughout the global industry.
Brands in the Sami-Sabinsa portfolio include Curcumin C3 Complex, C3 Reduct, BioPerine, Boswellin, ForsLean, Shagandha, Saberry, LactoSpore, LactoSporin and Cosmoperine.
The company is committed to sustainable and environment-friendly practices. Sami-Sabinsa’s most recent initiative has been to invest in alternative energy to power its manufacturing facilities. Another priority is to focus on sustainable raw material sourcing practices for the cultivation of numerous medicinal crops. This includes the recently added Plectranthus hadiensis and Picrorhiza kurroa programs.